Polyrizon Announces Positive In-Vitro Results For Its PL-16 Viral Blocker Candidate Against H1N1 Influenza

Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced positive in-vitro results for its product candidate, the PL-16 Viral Blocker, a proprietary nasal gel formulation, confirming a broad-spectrum viral blocking efficacy and reversible physical mechanism.

Polyrizon's formulation was evaluated for its ability to block infection by multiple respiratory viruses, including the influenza virus H1N1, using cell models. The results demonstrated a strong protective effect, as pre-treatment with the formulation effectively prevented viral-induced cytopathic effects and maintained high cell viability following viral exposure. PL-16 Viral blocker formulation exhibited consistent and robust protection without evidence of cytotoxicity, confirming both the safety and efficacy of the composition.